Ryvu Therapeutics S.A.

Warsaw Stock Exchange:RVU.WA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Poland

Market Cap

USD 190.06 M

Share Price

USD 8.22

Avg Daily Volume

109,116

Change (1 day)

1.95%

Change (1 year)

-37.20%

Change (YTD)

-12.08%

Ryvu Therapeutics S.A. Interest Coverage Ratio for the year ending December 31, 2024: -28.19

Ryvu Therapeutics S.A. Interest Coverage Ratio is -28.19 for the year ending December 31, 2024, a -97.03% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Ryvu Therapeutics S.A. Interest Coverage Ratio for the year ending December 31, 2023 was -948.62, a 1,222.62% change year over year.
Ryvu Therapeutics S.A. Interest Coverage Ratio for the year ending December 31, 2022 was -71.72, a -81.99% change year over year.
Ryvu Therapeutics S.A. Interest Coverage Ratio for the year ending December 31, 2021 was -398.15, a 410.31% change year over year.
Ryvu Therapeutics S.A. Interest Coverage Ratio for the year ending December 31, 2020 was -78.02, a -61.12% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)	Return on Assets (ROA)

Warsaw Stock Exchange: RVU.WA

Ryvu Therapeutics S.A.

CEO	Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
IPO Date	July 14, 2011
Location	Poland
Headquarters	Leona Henryka Sternbacha 2
Employees	328
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.